Adagrasib

CAS No.

2326521-71-3

MDL No.

MFCD32263433

C₃₂H₃₅ClFN₇O₂

604.10

InChI Key

PEMUGDMSUDYLHU-ZEQRLZLVSA-N

Pack Size	Purity	Price	Availability	Action
-	-	On Request	On Request
Custom synthesis and bulk supply options are available upon request.

Pack Size

Purity

Price

Availability

Action

On Request

Custom synthesis and bulk supply options are available upon request.

Product Information

Adagrasib (MRTX849) is an oral, small-molecule KRAS inhibitor developed by Mirati Therapeutics. KRAS mutations are prevalent in cancer, accounting for about 85% of all RAS family mutations.

CAS No.	2326521-71-3
Product Name	Adagrasib

Biological Targets

KRAS

Associated Conditions

colorectal cancer·Malignant Pancreatic Neoplasm·lung cancer·metastatic neoplasm·neoplasm·

* The information provided here is compiled from public sources and is for reference only.

Pricing & Availability

Product Information

Biological Profile

Safety Information

Properties

Biological Targets

Associated Conditions

Documentation

Adagrasib

Pricing & Availability

Product Information

Biological Profile

Safety Information

Properties

Biological Targets

Associated Conditions

Related Articles

Adagrasib: First Approval.

Activity of Adagrasib (MRTX849) in Brain Metastases: Preclinical Models and Clinical Data from Patients with KRASG12C-Mutant Non-Small Cell Lung Cancer.

Identification of the Clinical Development Candidate , a Covalent KRAS Inhibitor for the Treatment of Cancer.

Productivity prospers on the range.

Documentation

Similar Products

2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile